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Abstract 
Purpose: To determine the differences in response following the use of aldehyde dehydrogenase 1 
(ALDH1) and Raf kinase inhibitor protein (RKIP) as cervical cancer stem cell markers.  
Methods: To evaluate the cancer stem cell markers, a mouse model with low and high grade cervical 
cancer was developed and studied by histological examination. Immunohistochemical and Western 
blotting techniques were employed to study the expression profiles of ALDH1 and RKIP. The specificity 
of Sox2 that determines cancer stem cells served as control to validate ALDH1 and RKIP expressions.   
Results: Histological data helped to differentiate low from high grade cervical cancer. The results from 
immunohistochemistry show increased pattern of Sox2 expression as tumour progresses. Similarly, 
ALDH1, a protein that positively regulates stem cells shows mild expression in low grade cervical 
tumour, but positive signals are more amplified in an aggressive stage of tumour condition when 
compared with Sox2. The expression study with RKIP, a protein that negatively regulates stem cells, 
interestingly defines the higher expression in low grade cervical cancer to regulate the tumour, but 
shows little or no very mild expression in the aggressive stage of tumour. All the data obtained show a 
statistically significant value of p < 0.05. The results with Immunohistochemistry were further validated 
using the western blotting analysis and it also confirms the similar results. 
Conclusion: ALDH1 and RKIP marker in association correlation with Sox2 aids in defining the 
proliferative ability of cervical cancer stem cells and also to validate them in initial and advanced stages 
of cervical cancer.  
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On a global level, cervical cancer is reported to 
be the fourth most common cancer among 
women population [1]. Yearly, almost 470,000 
new cases are diagnosed with a malignant form 
of cervical cancer and 233,000 death cases are 
reported every year [2]. Chemotherapy, 
radiotherapy and surgery are handful to improve 
the survival of patients with cervical carcinoma 
[3], but in approximately 35 % of cases, after 
initial improvement, the disease starts to worsen 
within the time range of three years [4]. The 
recurrence of the disease implies that the 
resistance of cervical cancer cells or cancer stem 
cells that still remain after treatment gets 
triggered before their re-emergence. Cancer 
stem cells possess the ability of self-renewal and 
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differentiation to form matured cancer cells that 
are linked with tumour initiation, metastasis and 
recurrence [5]. The role of cancer stem cells was 
first identified in leukemias and later, were 
identified in solid tumours like brain [6], colon [7] 
and also in cervical cancers [8].  
 
The field research area of cancer stem cells is a 
newly developing field and identifying these cells 
is tricky at present. Most of the normal stem cell 
markers cannot effectively guide in the specific 
identification of cancer stem cells because it 
emerged from a specific mutation that takes 
place in stem cell population. Comparing the 
novel markers that show the under-expression 
and up-regulation in cancerous activity, helps to 
refine and identify the proliferative cancer stem 
cells. Aldehyde dehydrogenases (ALDH) are 
NAD(P)+  dependent detoxifying enzymes  that 
determines cell survival ability was initially 
identified established as a stem cell marker in 
haematopoietic stem cells [9]. A high expression 
of ALDH can also used to distinguish neural stem 
cells [10]. The ALDH activity can also be a useful 
cancer stem cell marker because it determines 
metastasis and cell survival [11]. It is 
successfully used as a stem cell marker for many 
cancer types including cervical cancer [12].  The 
current study defines the role of ALDH as a 
cancer stem cell marker that vary among 
different cancer types and also within the same 
tumour cell lines [13]. The Raf kinase inhibitor 
protein (RKIP) was identified as a metastasis 
suppressor in many tumour types like in prostate 
cancer [14], colorectal cancer [15] and in cervical 
cancer [16]. But these markers suffer from poor 
prognosis in cervical cancer, as well as in other 
cancer types [17,18]. In this paper, we have 
selected a pair of over-expression and under-
expression markers namely ALDH and RKIP, to 
understand the proliferative nature of cancer 
stem cells in a cervical cancer mice model so 






The animals were handled following the 
guidelines for using experimental animals [19]. 
For experimental purpose, the female strain of 
nude athymic mice (BALB/c-nu/nu), aged 8 
weeks was uniformly chosen. The HeLa cells 
grown in a serum free medium were dissociated 
to obtain individual cells. The cells were then 
resuspended in 100 μl of FBS and growth factor-
free DMEM at a cell density of 1 × 105 cells [8]. 
The obtained cells were then injected 
subcutaneously into the left and right flanks [8]. 
The injected athymic mice were monitored and 
provided water, feed and maintained in dust free 
laboratory condition [20] for eight weeks. The 
tumour samples were collected in initial 
development stage of the tumour initiation (on 
the 4th week) and in the aggressive stage of the 
tumour condition (on the 8th week) by scarifying 




For performing immunohistochemistry, the tissue 
sections were initially fixed in 10 % formalin 
solution, and after dehydration and clearing, the 
tissues were paraffin embedded. The tissue 
sections were then subjected to microtome 
sectioning of size 6 µm. The sections were then 
carefully placed on glass slides and were de-
paraffinized and then rehydrated. The 
endogenous peroxidase activity was blocked by 
immersing the sections in freshly prepared 10 % 
H2O2 and 10 % Methanol with 1X PBS for 20 
mins. Trypsin treatment (0.1 % trypsin in 0.1 % 
CaCl2) was maintained for 10 min to cleave the 
protein cross link, so as to assess the antigen 
and epitope. The non-specific antigens were 
blocked using 4 % of BSA and then were 
incubated with suitable primary antibody (Anti-
ALDH1 antibody, Abcam (EP1933Y); Anti-Sox2 
antibody, Abcam (ab92494); anti-RKIP Antibody, 
Santa cruz (SC-28837) overnight at 4 oC. After 
incubation, the sections were thoroughly washed 
with 1X PBS and latter incubated with a suitable 
secondary antibody for 30 min at room 
temperature. After washing the non-specific 
binding, the sections were stained with DAB 
(diaminobenzidine) Kit.  
 
Western blot analysis 
 
The samples from normal tissue, initial stage and 
samples from advanced stages of cervical 
cancer were dissected and the protein samples 
were prepared from the cell lysate. The cellular 
proteins were resolved in 12 % SDS-PAGE gel 
by following the protocol as described [22]. The 
protein in the gel was then transferred to the 
PVDF membrane. After blocking the membrane 
overnight at 4 ºC, they were incubated with an 
appropriate dilution of the primary antibody (Anti-
ALDH1 antibody, Abcam (EP1933Y); Anti-Sox2 
antibody, Abcam (ab92494); anti-RKIP Antibody, 
Santa cruz (sc-28837) according to the 
manufacturer’s instruction. The membranes were 
then incubated with the suitable secondary 
antibody of dilution concentration (1:3000). After 
following washing, the membrane was developed 
to obtain the signal. 
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The results are presented as mean ± standard 
deviation (SD) and were analysed by analysis of 
variance (ANOVA). The software used for the 
analysis was Microsoft Office Excel 2007. P < 




Mice model to study cervical cancer 
 
Studies carried out with the cell lines of cervical 
cancer to find out new markers of cancer stem 
cells varies in result even within a particular 
tumour cell line and it requires different 
understanding [13].  Therefore, studying and 
assessing the cancer stem cells markers in an 
identical animal model was more valuable. 
Cervical cancer was developed in the in vivo 
model of mice as described in the materials and 
methods.  
 
After injection with HeLa cells, the mice 
developed the initial stage of cervical cancer on 
the 4th week and more advanced stages of the 
tumour on the 8th week of post injection as 
visualized in the histological sections (Fig 1). The 
histology of the normal cervical tissue sections 
shows the regular arrangement of a cellular 
pattern with less cell density (Fig 1A). As the 
tumour starts to developed, the proliferative cells 
starts to increase during the initial stage on the 
4th week (Fig 1B) and reach its maximum during 
the advance stage of cervical cancer (Fig 1C). 
 
Comparing Sox 2 expression with ALDH and 
RKIP 
 
The Sox2 expression was tightly correlated 
linked with the progression of many human 
malignancies [23] and it was effectively used in 
breast cancer and glioblastoma as a cancer stem 
cell marker [24,25]. The correlation association 
between Sox2 expression with cervical cancer 
stem cell population is also well documented 
[23]. Another interesting correlation is that the 
depletion in Sox2 expression is linked with the 
reduction of the transformational properties of the 
cell [26]. In this study, we used the Sox2 as a 
standard maker to determine the role of ALDH 
and RKIP in determining the proliferation ability 
of cervical cancer stem cells. 
 
Immunohistochemical analysis of normal cervical 
tissue shows limited positive cells for Sox 2 
expression (Fig 2A). As the tumour progressed, 
the population of Sox2 positive cells shows 
concurrent increase in number by the 4th week 
of the initial stage of cervical cancer (Fig 2B) and 
their expression reached its maximum on the 8th 
week of the advanced stage of the cervical 
cancer (p < 0.05) (Fig 2C).  Similarly, the ALDH1 
expression also shows high-regulated expression 
as the tumour progressed (Fig 2D-F).  
 
The proposition of ALDH1 positive cells were 
limited in normal tissue (Fig 2D) and their 
expression starts to increase in the primary stage 
of cancer (Fig 2E).  
 
 
Figure 1: Mice model with low and high grade cervical cancer. A. Histological section of normal cervical tissue 
which shows regular arrangement of cells B. Histology of low grade cervical tumour with moderate cell 
proliferation. C. Histology of high grade cervical tumour with extreme cell proliferation. Scale Bar = 50µm size 
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As the tumour progressed to a severe stage on 
the 8th week, the ALDH1 expression shows the 
maximum extent (p < 0.05). The study was 
further extended to find out the positive 
regulation of RKIP in tumour regulation. In the 
control tissue, the RKIP directs higher expression 
(Fig 2G) and acts as positive regulator that keeps 
check on the tumour progression. Interestingly, in 
the initial stage of the tumour, their expression 
gets up-regulated (Fig 2H) but in the advanced 
stage of the tumour development, their 
expression gets down-regulated as expected (p 
< 0.05) (Fig 2I). 
 
Western blotting results 
 
For better understanding of the correlation that 
the Sox2 expression has with ALDH1 and RKIP, 
the immunohistochemical data was further 
validated using western blotting analysis. 
 
 
Figure 2: Upregulation of Sox2 expression correlate with ALDH1 and RKIP expression. A. Image represents the 
normal cervical tissue with less expression of Sox2 protein. B. Low grade cervical tumour shows mild expression 
of Sox2. C. High grade tumour with over expression of Sox2. D. Control tissue with little expression of ALDH1 
protein. E. initial stage of cervical cancer with average expression pattern of ALDH1. F. advance stage of cervical 
cancer with more expression of ALDH1. G. Normal cervical tissue with moderate expression of RKIP. H. Low 
grade cervical tumour showing higher expression of RKIP protein. I. High grade tumour with little or no 
expression of RKIP protein.  Scale Bar = 100µm size 
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Figure 3: Validation of Sox2, ALDH1 and RKIP expression by western blot analysis. Lane 1 represents the Sox2 
expression in normal cervical tissue. Lane 2 shows the Sox2 protein expression in low grade cervical tumour. 
Lane 3 specifies Sox2 protein expression in high grade cervical tumour. Lane 4 shows ALDH1 expression in 
normal cervical tissue.  Lane 5 represents ALDH1 expression in initial cervical tumour. Lane 6 represents ALDH1 
expression in high proliferative cervical tumour. Lane 7 represents the RKIP expression in normal cervical tissue. 
Lane 8 shows the RKIP protein expression in low grade cervical tumour. Lane 9 specifies RKIP protein 
expression in high grade cervical tumour. β-Actin was used as a loading control 
 
The results with western blotting analysis 
demonstrate shows that the protein expression 
profile of Sox2 dramatically increased as the 
tumour progressed as shown in first three lanes 
of Fig 3. Similarly, increased the up regulated 
expression of ALDH1 with significant 
enhancement of ALDH1 expression in the 
advanced stage of the cervical cancer was noted 
as shown in lane four to six of Fig 3. But when 
compared with the control tissue, we observed 
that the RKIP expression showed elevated 
expression profile in the initial stage of the 
tumour and down-regulated latter in the advance 
stage of the tumour progression development as 




The connections between stem cell markers with 
different pathological conditions of cancer were 
still poorly investigated. Recently it was revealed 
that new stem cell markers emerged while 
studying the process of tumour initiation and 
progression [27]. The present study was carried 
out with a well-documented stemness associated 
marker named Sox2 [23]. Using this standard 
marker, we evaluated assess the expression of 
ALDH1 and RKIP which are less sensitive 
markers, in different in vivo pathological 
conditions.  
 
In recent studies of prostate cancer, the 
expression of ALDH1 shows relatively lower 
expression instead of high expression, but the 
result with other isoforms of ALDH remains the 
same [28]. Thus the results with ALDH1 are 
needed to be validated further; especially in their 
in vivo condition. In our study, the mice model 
responded well in the tumour formation and it 
formed low grade as well as higher grade 
tumours (Fig 1B,C) that helps to study the 
function of different proteins in tumour 
progression. The results obtained with an 
immunohistochemical against ALDH1, shows 
extensively high label proliferative cells in the 
advance stage of cervical cancer (Fig 2F) and 
the obtained result was consistent reliable with 
previously already reported data [12]. The higher 
the population of ALDH1 positive cells, the more 
revealed is their role in tumourigenicity and 
metastasis and their correlation is parallel with 
the cervical cancer stem cells that are identified 
using Sox2 (Fig 2A-C). The study of RKIP 
expression in various grade of tumour, reveals 
that in the initial stages of the tumour, the RKIP 
has a control over tumour development with 
higher expression (Fig 2H), but at the higher 
grade of the tumour their control over the tumour 
was relaxed with lower expression (Fig 2I). 
Comparing the results along with Sox2, the 
higher expression upregulated profile of ALDH1 
and lower expression of RKIP might also be 




The expression pattern of ALDH1 and RKIP are 
tightly regulated in cancer stem cells in advanced 
stages of cervical cancer but they show 
disordered expression in initial stages of cervical 
cancer. 
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